AVR (ASX) EGM update

Originally posted by dgoynich ↑

I'll start by saying I've already voted Yes to all and imo the only sane thing you can do if you want the business the thrive rather than just survive...or worse...

When WP took over and attracted medtech professionals to the board - ditching the old mining crew, he could see the potential of adapt.

At the time, Admedus didn't have Scott bliss the ex Baxter engineer and they also didnt quite understand what they could do with cardiocel and the adapt tissue but they new it was special.

The road map wasn't that great and was filled with flat tissue products with the standout being stem cells.

If you could see the top secret road map today (I have) you'd realise the flat patches are yesterday's news. 3d was just a tester and proof of concept. The new road map is filled with unique high margin high profitability products.

3d precipitated and helped bring to life TAVR but it ain't cheap. We have an advisory board which does cost money BUT is fast tracking delivery and has improved vastly in the original concept to the point whereby one of the leading surgeons on the advisory board who helped another firm develop their leading Tavr stated we are miles in front already. That's a multibillion dollar yearly revenue stream we can enter and take over... if we have the cash to finish the job!

Now... recent communications with Wayne... he stated we have a few other catheter based projects aside from TAVR. TAVR is not the only one.
Heck 3d is not our only 3d tissue product and it certainly isn't the largest market... But we need cash to develop more.

The shaped portfolio is unique in that it allows AHZ to develop shaped products that target specific types of surgery and make it much quicker to perform as adapt doesn't require washing (up to 45mins time saving in the theater); and fits the specific need with being cut or folded or kinked inside the patient.

In each one of these cases there is the opportunity to displace all serious competitors. One by one we take their market and destroy their market share.

And we do this without calcification or rejection of the tissue.

BUT... we can't develop these products without cash. It takes money to engineer, gain approval, test in animals and patients.

It doesn't take infinite amounts of cash but more than we had.

So by voting no and imo you are potentially killing your own golden goose. It's got NOTHING to do with dilution- it's got nothing to do with lotto. It's got to do with return on investment.

A different counter example to lotto would be investing in a mining company whereby you continually get diluted but the resource in the ground isn't growing. It's a finite resource so every dilution minimises your share of that resource.

With AHZ the potential resource is continually getting bigger by providing the funds to grow a portfolio. If what WP is saying is true, then the very real outcome and potential is that even if you don't contribute to a CR, you can still significantly more than benefit by allowing a CR to proceed.

So I understand if one personally does not want to contribute to a "potential" further cr... But don't cut off your nose despite your face and don't destroy your golden goose. I expect WP and the board to fully pursue ANY and ALL realistic opportunities... sadly we are hamstrung by lack of cash and limiting our own growth.

So I think voting no is incredibly short sighted given the potential and I've seen no structured counter argument from anyone.

gltah and dyor
Cheers
David

Expand

I appreciate your insights. As you're so in touch with WP, please do ask him this and enlighten us:

Why does he have so little skin in the game? (Does he not believe in his own potential to deliver?)

What kind of management forces its investors to turn out their pockets to protect their own investments?

Go well, and I hope for management's sake that they can and will take up their full allotments at 30c

No.	Vol.	Price($)
1	4	$11.80

No.

Vol.

Price($)

$11.80

Price($)	Vol.	No.
$11.90	251	1

Price($)

Vol.

No.

$11.90

251

No.	Vol.	Price($)
1	4	11.800
1	86	11.620
1	1000	11.520
2	543	11.500
1	50	11.350

No.

Vol.

Price($)

11.800

11.620

1000

11.520

543

11.500

11.350

Price($)	Vol.	No.
11.900	251	1
12.000	512	2
12.070	1000	1
12.100	1220	1
12.290	282	1

Price($)

Vol.

No.

11.900

251

12.000

512

12.070

1000

12.100

1220

12.290

282

(20min delay)
Last $11.80		Change -0.760(6.05%)		Mkt cap ! $249.4M

Open	High	Low	Value	Volume
$12.49	$12.49	$11.30	$234.2K	19.65K

I appreciate your insights. As you're so in touch with WP,...

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

EBR Systems' heart pacing device on-target to reach the US market

SKS secures $20M for extension works on Melbourne data centre

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I appreciate your insights. As you're so in touch with WP,...

Top Stories

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

EBR Systems' heart pacing device on-target to reach the US market

SKS secures $20M for extension works on Melbourne data centre

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News